Kura Oncology, Inc.

Equities

KURA

US50127T1097

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
21.17 ^USD	-1.21%		-4.51%	+47.22%

24/05	Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001	CI
15/05	Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM

Kura Oncology, Inc. Appoints Mary Szela to its Board of Directors

November 08, 2018 at 07:00 pm IST

Kura Oncology, Inc. announced the appointment of commercial veteran Mary Szela to its board of directors. She currently serves on the board of Coherus Biosciences, Alimera Sciences and TriSalus Life Sciences.

Latest news about Kura Oncology, Inc.

Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001	25/05	CI
Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM	15/05
Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug	14/05	MT
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML	14/05	CI
Transcript : Kura Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024	03/05
Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Sector Update: Health Care Stocks Advance Premarket Monday	22/04	MT
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy	22/04	DJ
Kura Oncology Says Potential Leukemia Drug Ziftomenib Gets FDA Breakthrough Therapy Designation; Shares Rise Pre-Bell	22/04	MT
Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML	22/04	CI
Transcript : Kura Oncology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:00 AM	14/03
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	06/03	CI
Transcript : Kura Oncology, Inc., 2023 Earnings Call, Feb 27, 2024	28/02
Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02	CI
Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia	26/02	CI
Kura Oncology Says Study of Leukemia Combination Therapy Yields Positive Early Data	30/01	MT
Transcript : Kura Oncology, Inc. - Special Call	30/01
Top Premarket Gainers	30/01	MT
Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia	30/01	CI
Kura Oncology, Inc. announced that it has received $150 million in funding from EcoR1 Capital, LLC	26/01	CI
Kura Oncology Expects to Raise $150 Million in Gross Proceeds From Oversubscribed Private Placement	24/01	MT
Top Premarket Gainers	24/01	MT
Kura Oncology, Inc. announced that it expects to receive $150 million in funding from EcoR1 Capital, LLC	24/01	CI
Mizuho Securities Initiates Kura Oncology With Buy Rating, Price Target is $26	22/12	MT

Chart Kura Oncology, Inc.

Duration

Period

More charts

Company Profile

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

Sector

Biotechnology & Medical Research

Calendar

05/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.17 USD

Average target price

30.25 USD

Spread / Average Target

+42.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KURA ONCOLOGY, INC.	+47.22%	161.27Cr
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.15%	11TCr
BIONTECH SE	-8.14%	2.34TCr
ARGENX SE	-1.69%	2.18TCr
GENMAB A/S	-10.60%	1.81TCr
WUXI APPTEC CO., LTD.	-41.25%	1.67TCr
BEIGENE, LTD.	-15.33%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+5.80%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+28.03%	1.17TCr

Bio Therapeutic Drugs